Short answer
HAEMONETICS CORP (HAE) filed its fiscal 2025 10-K annual report with the SEC on May 21, 2025. It reported revenue of $1.4B (+4.0% year over year) and net income of $168M.
- Top risk flagged: Regulatory risk from SEC Rule 10b5-1 affecting timing and execution of $500M share repurchase program through April 2028
FY2025 key financial metrics · XBRL
- Revenue
- $1.4B
- +4.0% YoY
- Net income
- $168M
- +42.6% YoY
- Operating margin
- 16.3%
- +3.7 pp YoY
- Gross margin
- 55.0%
- +2.2 pp YoY
- EPS (diluted)
- $3.31
- +44.5% YoY
- ROE
- 20.4%
- +8.2 pp YoY
- Operating cash flow
- $182M
- −0.0% YoY
Source: XBRL data from the HAEMONETICS CORP (HAE) FY2025 10-K on SEC EDGAR. USD.
HAEMONETICS CORP FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Medical devices and technologies for plasma collection, blood centers, and hospitals
- Emphasis on Plasma and Hospital segments as primary growth drivers; Blood Center focused on targeted plasma and platelet opportunities
- Strategic divestiture of Whole Blood product line to align portfolio with long-term objectives
- Top 10 customers accounted for 42% of net revenues in fiscal 2025; largest Plasma customer contract extended non-exclusively through Dec 2025
- New market and regional alignment initiative approved in fiscal 2026 aimed at cost reduction and operational performance improvement
Management Discussion & Analysis
- Revenue $1.361B, up 4.0% YoY; Hospital segment up 23.7% ($564M vs $456M), Plasma down 6.0% ($535M vs $570M), Blood Center down 7.8% ($261M vs $283M)
- Operating margin 16.3% vs 12.6%; gross margin 55.0% vs 52.8%; net income margin 12.3% vs 9.0%
- Best performing segment Hospital with 23.7% growth to $564M; worst Blood Center with 7.8% decline to $261M
- Share repurchase: $300M completed with new $500M authorization; Capex and acquisition spending includes $187.7M for Attune Medical, $254.5M for OpSens; $65.8M cash received from divestiture of Whole Blood product line
- Forward outlook: $20M restructuring charge expected through FY2027 with annualized $30M savings; focus on growth in Plasma and Hospital; risks from foreign exchange and market dynamics noted
Risk Factors
- Regulatory risk from SEC Rule 10b5-1 affecting timing and execution of $500M share repurchase program through April 2028
- Share repurchase program could increase stock price volatility and reduce market liquidity for common stock
- Share repurchases constrained by compliance with loan covenants impacting cash flow flexibility
- Potential stock price decline below repurchase cost risking shareholder value erosion
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.